Bioxytran Completes Production of Two Dietary Supplements: V-LO® for Immune Health and A-SUQAR® for Healthy Blood Sugar
The nutraceutical business operates separately from Bioxytran's pharmaceutical development programs.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bioxytran (OTCQB: BIXT) has completed production of two dietary supplements as it prepares to bring its first consumer products to market. Finished inventory is available for V-LO®, formulated to support normal immune function, and A-SUQAR®, formulated to support healthy post-meal blood sugar levels already within the normal range.
The company is finalizing marketing and sales plans covering e-commerce, retail, distribution partners and initial geographic markets. Bioxytran expects to announce launch timing and availability once those plans are finalized. In February 2026, it entered into a commercial distribution agreement with Khoury Medical to commercialize A-SUQAR® in the Middle East.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointKhoury Medical distribution agreement signed in February 2026 covers A-SUQAR® commercialization in the Middle East.
- Minor pointFinished inventory of both supplements has been manufactured ahead of planned marketing and sales.
- Minor point. Forward-looking: it has not happened yet and may not happen.Go-to-market plans under development include e-commerce, retail and distribution-partner channels.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Launch timing and availability await finalization of marketing and sales plans.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Finished inventory of both products has been manufactured; Company is finalizing go-to-market plans
Boston, MA, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) ("Bioxytran" or the "Company"), a biotechnology company developing carbohydrate-based technologies, today announced that it has completed production of two dietary supplements: V-LO®, formulated to support normal immune function, and A-SUQAR®, formulated to support healthy post-meal blood sugar levels already within the normal range. Both product names are registered trademarks with the United States Patent and Trademark Office (USPTO). The Company has produced finished inventory of both products in anticipation of commencing marketing and sales.
V-LO®: Immune Health Support
V-LO® is a dietary supplement designed to support normal immune function. It is a 2-gr. polysaccharide chewable tablet from natural plant taken 5 times a day.
How It Works
V-LO® is formulated with a complex carbohydrates selected for their role to support the body's normal immune response on normal immune function in healthy people, The polysaccharides are Generally Regards as Safe and register by the FDA in the pharmacopeia and supported by evidence on V-LO® or its ingredients at the dose provided.
V-LO® enters one of the largest segments of the nutraceutical industry. According to Research and Markets, the global immune health supplements market is projected to reach approximately USD 40.0 billion in 2026 and to grow at a compound annual growth rate (CAGR) of
A-SUQAR®: Healthy Blood Sugar Support
A-SUQAR® is an oral chewable tablet taken before a meal to support healthy post-meal blood sugar levels already within the normal range. It contains proprietary partially hydrolyzed polysaccharide formulation and was developed based on scientific and manufacturing expertise. In February 2026, Bioxytran entered into a commercial Distribution Agreement with Khoury Medical LTD to commercialize A-SUQAR® in the middle east.
How It Works
The natural polysaccharide from plant source is a soluble dietary fiber derived from plant cell walls with a long history of use in foods. Taking one or two chewable tablets before a meal as part of a balanced diet, A-SUQAR® is designed to work in the digestive tract while a meal's carbohydrates are being digested. A-SUQAR® blocks the enzymes which digest sugars in the food and helping to moderate the rise in blood sugar that normally follows eating.
The global glucose management supplements market was valued at approximately USD 9.9 billion in 2025 and is projected to reach USD 15.4 billion by 2032, a CAGR of
"Completing production of V-LO® and A-SUQAR® is an important step as we prepare to bring our first consumer products to market," said David Platt, Ph.D., Chief Executive Officer of Bioxytran. "Both products reflect our team's long experience in carbohydrate chemistry. With inventory produced, our focus now is on finalizing our marketing and sales plans and building the right channels for each product."
With complete manufacturing, Bioxytran is finalizing its go-to-market plans, including e-commerce, retail and distribution-partner channels and initial geographic markets. The Company expects to announce launch timing and availability once those plans are finalized. The nutraceutical business is operated separately from the Company's pharmaceutical development programs.
About Bioxytran, Inc.
Bioxytran, Inc. (OTCQB: BIXT) is a clinical-stage biotechnology company developing platform technologies in Glycovirology, hypoxia and degenerative disease using carbohydrate drug design, including programs that leverage galectin receptors inhibition and programs that address hypoxic conditions and tissue oxygenation. For more information, visit www.bioxytraninc.com
Dietary Supplement Disclaimer
These statements have not been evaluated by the Food and Drug Administration. V-LO® and A-SUQAR® are not intended to diagnose, treat, cure or prevent any disease.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the expected marketing, sales and commercial launch of V-LO® and A-SUQAR®, anticipated market opportunities and Bioxytran's future business plans. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. These include, among others: the Company has not yet generated revenue from sales of V-LO® or A-SUQAR® and may not do so; market acceptance of the products; the Company's ability to establish marketing, sales and distribution channels; compliance with U.S. Food and Drug Administration, Federal Trade Commission and foreign laws and regulations governing dietary supplements, including requirements relating to product claims, labeling and substantiation, and the possibility of regulatory action; the regulatory status of the products in each market where they are sold; manufacturing and supply; competition; and the Company's ability to secure financing. Additional risks are described in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Third-party market estimates are provided for context only; they describe overall industry size and are not a forecast of the Company's sales. Bioxytran undertakes no obligation to update or revise any forward-looking statements, except as required by law.
Media and Investor Contact
David Platt, Ph.D., Chief Executive Officer
Bioxytran, Inc.
Info@bioxytraninc.com
Tel: 617.454.1199
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Has Bioxytran completed production of V-LO and A-SUQAR?
Bioxytran has completed production and manufactured finished inventory of both V-LO® and A-SUQAR®. Marketing and sales plans are still being finalized, and the company expects to announce launch timing and availability after that work is complete.
Are Bioxytran's V-LO and A-SUQAR intended to treat disease?
V-LO® and A-SUQAR® are not intended to diagnose, treat, cure or prevent any disease. Their dietary supplement statements have not been evaluated by the Food and Drug Administration.